PL415073A1 - Podstawione aminotriazole przydatne jako inhibitory kwaśnej chitynazy ssaków - Google Patents

Podstawione aminotriazole przydatne jako inhibitory kwaśnej chitynazy ssaków

Info

Publication number
PL415073A1
PL415073A1 PL415073A PL41507315A PL415073A1 PL 415073 A1 PL415073 A1 PL 415073A1 PL 415073 A PL415073 A PL 415073A PL 41507315 A PL41507315 A PL 41507315A PL 415073 A1 PL415073 A1 PL 415073A1
Authority
PL
Poland
Prior art keywords
substituted amino
mammalian chitinase
acidic mammalian
amino triazoles
compounds
Prior art date
Application number
PL415073A
Other languages
English (en)
Inventor
Adam Gołębiowski
Robert Koralewski
Wojciech Czestkowski
Krzysztof Matyszewski
Sylwia Olejniczak
Jacek Olczak
Paul R. Beckett
Original Assignee
Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością filed Critical Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością
Priority to AU2015363761A priority Critical patent/AU2015363761B2/en
Priority to EP15825641.2A priority patent/EP3233832B1/en
Priority to PCT/PL2015/050071 priority patent/WO2016099311A1/en
Priority to CN201580076502.5A priority patent/CN107428720B/zh
Priority to PL15825641T priority patent/PL3233832T3/pl
Priority to CA2971395A priority patent/CA2971395A1/en
Publication of PL415073A1 publication Critical patent/PL415073A1/pl
Priority to ZA2017/04879A priority patent/ZA201704879B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G01N2333/942—Hydrolases (3) acting on glycosyl compounds (3.2) acting on beta-1, 4-glucosidic bonds, e.g. cellulase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Ujawnione są związki aminotriazolowe podstawione grupą funkcyjną karboksylanową albo bioizosteryczną polarną grupą funkcyjną. Związki mające ugrupowanie karboksylanowe albo bioizosteryczną polarną grupę funkcyjną hamują kwaśną chitynazę ssaków. Także podane są sposoby stosowania związków do leczenia reakcji astmatycznych powodowanych przez alergeny.
PL415073A 2014-12-19 2015-12-04 Podstawione aminotriazole przydatne jako inhibitory kwaśnej chitynazy ssaków PL415073A1 (pl)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2015363761A AU2015363761B2 (en) 2014-12-19 2015-12-18 Substituted amino triazoles useful as acidic mammalian chitinase inhibitors
EP15825641.2A EP3233832B1 (en) 2014-12-19 2015-12-18 Substituted amino triazoles useful as acidic mammalian chitinase inhibitors
PCT/PL2015/050071 WO2016099311A1 (en) 2014-12-19 2015-12-18 Substituted amino triazoles useful as acidic mammalian chitinase inhibitors
CN201580076502.5A CN107428720B (zh) 2014-12-19 2015-12-18 用作酸性哺乳动物壳多糖酶抑制剂的取代的氨基三唑
PL15825641T PL3233832T3 (pl) 2014-12-19 2015-12-18 Podstawione aminotriazole przydatne jako inhibitory kwaśnej chitynazy ssaków
CA2971395A CA2971395A1 (en) 2014-12-19 2015-12-18 Substituted amino triazoles useful as acidic mammalian chitinase inhibitors
ZA2017/04879A ZA201704879B (en) 2014-12-19 2017-07-18 Substituted amino triazoles useful as acidic mammalian chitinase inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462094446P 2014-12-19 2014-12-19

Publications (1)

Publication Number Publication Date
PL415073A1 true PL415073A1 (pl) 2016-06-20

Family

ID=56120793

Family Applications (2)

Application Number Title Priority Date Filing Date
PL415073A PL415073A1 (pl) 2014-12-19 2015-12-04 Podstawione aminotriazole przydatne jako inhibitory kwaśnej chitynazy ssaków
PL15825641T PL3233832T3 (pl) 2014-12-19 2015-12-18 Podstawione aminotriazole przydatne jako inhibitory kwaśnej chitynazy ssaków

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL15825641T PL3233832T3 (pl) 2014-12-19 2015-12-18 Podstawione aminotriazole przydatne jako inhibitory kwaśnej chitynazy ssaków

Country Status (8)

Country Link
US (2) US9440953B2 (pl)
EP (1) EP3233832B1 (pl)
CN (1) CN107428720B (pl)
AU (1) AU2015363761B2 (pl)
CA (1) CA2971395A1 (pl)
PL (2) PL415073A1 (pl)
WO (1) WO2016099311A1 (pl)
ZA (1) ZA201704879B (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL415078A1 (pl) * 2015-09-04 2017-03-13 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Podstawione aminotriazole przydatne jako inhibitory kwaśnej chitynazy ssaków
MX2022000306A (es) 2019-07-15 2022-03-11 Oncoarendi Therapeutics Sa Amino triazoles sustituidos utiles como inhibidores de quitinasa.
MX2022002881A (es) 2019-09-25 2022-06-08 Oncoarendi Therapeutics Sa Proceso para la produccion de 5-(4-((2s,5s)-5-(4-clorobencil)-2-me tilmorfolino)piperidin-1-il)-1h-1,2,4-triazol-3-amina.
US11912647B2 (en) 2020-05-22 2024-02-27 University Of Georgia Research Foundation, Inc. Diversity-oriented synthesis of N,N,O-trisubstituted hydroxylamines from alcohols and amines by N—O bond formation
CN111732571B (zh) * 2020-07-24 2021-06-29 广西壮族自治区农业科学院 一种用于防治香蕉枯萎病的杀植物真菌剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4276297A (en) * 1979-06-18 1981-06-30 Pfizer Inc. Pyridylaminotriazole therapeutic agents
US4421753A (en) * 1982-01-15 1983-12-20 American Cyanamid Company 1-(5-Amino-4H-1,2,4-triazol-3-yl)-4-substituted-piperazines
JP3507486B2 (ja) 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
EP3082805B1 (en) 2013-12-20 2020-02-05 Institute for Drug Discovery, LLC Substituted amino triazoles, and methods using same

Also Published As

Publication number Publication date
EP3233832A1 (en) 2017-10-25
EP3233832B1 (en) 2019-11-20
CA2971395A1 (en) 2016-06-23
US20160176843A1 (en) 2016-06-23
AU2015363761B2 (en) 2020-07-09
ZA201704879B (en) 2020-01-29
US9440953B2 (en) 2016-09-13
CN107428720B (zh) 2020-06-30
US20160368894A1 (en) 2016-12-22
CN107428720A (zh) 2017-12-01
WO2016099311A1 (en) 2016-06-23
WO2016099311A4 (en) 2016-09-09
PL3233832T3 (pl) 2020-06-29
AU2015363761A1 (en) 2017-07-20

Similar Documents

Publication Publication Date Title
CR20160098A (es) Polimorfo de los inhibidores de la syk
EA201792519A1 (ru) Противогрибковые соединения
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
HK1245019A1 (zh) 吡啶酰胺化合物作爲杀真菌剂的用途
BR112017006253A2 (pt) novos compostos
EA201692143A1 (ru) Производные аминопиразина в качестве ингибиторов фосфатидилинозитол-3-киназы
EA201690844A1 (ru) Ингибиторы gsk-3
MX378963B (es) Compuestos de naftiridina como inhibidores de quinasa jak.
EA201692219A1 (ru) Способы получения противовирусных соединений
AU2015374459A8 (en) Picolinamide compounds with fungicidal activity
MX2017008444A (es) Picolinamidas como fungicidas.
EA201790112A1 (ru) Гетероциклические соединения и их применение в качестве ингибиторов орфанного рецептора гамма-t, родственного рецепторам ретиноидов (ror)
BR112016029333A2 (pt) síntese de compostos de carbamoilpiridona policíclico
PH12017500048A1 (en) Pyridone derivative having tetrahydropyranylmethyl group
EA201600344A1 (ru) Гербицидные соединения
BR112017006349A2 (pt) derivados de ácido borônico
PL415073A1 (pl) Podstawione aminotriazole przydatne jako inhibitory kwaśnej chitynazy ssaków
BR112017007194A2 (pt) compostos de hidroxil purina e aplicações dos mesmos
MX387796B (es) Compuestos de aminocarbonilcarbamato.
CY1118079T1 (el) Μεθοδος παρασκευης του αλατος l-αργινινικης περινδοπριλης
EP3498275C0 (en) Use of known compounds as d-amino acid oxidase inhibitors
ECSP19013196A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
AU2014378413A1 (en) Emulsion composition for skin
BR112016027455A2 (pt) moduladores ppar
MX2017010901A (es) Colorantes de acido trisazo.